Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.

The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible people, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction,[8] although a 1998 review has found such side-effects to rarely occur in people taking triptans.

GLADIATOR is an open-label study that compared 100 and 200 mg doses of lasmiditan in subjects that received the drug as part of a prior trial.

The primary result showed a statistically significant improvement in pain relief relative to placebo 2 hours after the first dose.

The secondary result showed a statistically significantly greater percentage of subjects were free of their most bothersome symptom (MBS) compared with placebo at two hours following the first dose.

[21] The applicant for this medicinal product is Eli Lilly Nederland B.V.[21] Rayvow was approved for medical use in the European Union in August 2022.

However, Health Canada and Eli Lilly could not come to agreement on the interpretation of the cardiovascular data and how it would be worded in the product monograph.